Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINIER phase 3 study of povetacicept in adults with IgA nephropathy
jRCT2041240119Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Povetacicept with Placebo (2 arms). Primary endpoints: Change from baseline in 24-hour urine protein to creatinine ratio at Week 36 and Total estimated glomerular filtration rate slope through Week 104. Started Feb 2025; status: active, not recruiting.
02
Drugs
povetacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2041240119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240119.